Literature DB >> 30810915

Paliperidone Long-Acting Injections in Huntington's Disease for Motor and Behavioural Disturbances.

Nameer van Oosterom1,2, Theo Theodoros3,4.   

Abstract

Oral antipsychotics are used to treat motor and behavioural disturbances in Huntington's disease (HD). However, patients with behavioural disturbances are often non-compliant, thus the oral route is inappropriate. The effects of antipsychotic long-acting injections (LAI) in HD are significantly underrepresented in literature. Paliperidone LAI (P-LAI), an atypical antipsychotic, has benefits over other antipsychotics LAI with its long dosing interval and no initial oral overlap, but has no documented cases for this indication. This case of a 45-year-old female highlights the use of P-LAI for severe aggression and chorea secondary to HD causing failed placement in assisted-care accommodation and mobility via an electronic-wheelchair. Three weeks after commencing treatment, she could walk unassisted, and displayed no aggression. After 10 months, she still had significant improvements and resided in the same accommodation for 6 months without any concern. Thus, this case suggests that P-LAI may be a treatment option for non-compliant HD patients.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30810915     DOI: 10.1007/s40261-019-00759-8

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  8 in total

1.  A new self-rating scale for detecting atypical or second-generation antipsychotic side effects.

Authors:  L Waddell; M Taylor
Journal:  J Psychopharmacol       Date:  2008-05       Impact factor: 4.153

2.  Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders.

Authors:  Cherrie Galletly; David Castle; Frances Dark; Verity Humberstone; Assen Jablensky; Eóin Killackey; Jayashri Kulkarni; Patrick McGorry; Olav Nielssen; Nga Tran
Journal:  Aust N Z J Psychiatry       Date:  2016-05       Impact factor: 5.744

3.  Risperidone long-acting injection and Huntington's disease: case series with significant psychiatric and behavioural symptoms.

Authors:  Timothy Graeme Johnston
Journal:  Int Clin Psychopharmacol       Date:  2011-03       Impact factor: 1.659

4.  Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS) as a subjective measure of drug-induced parkinsonism and akathisia.

Authors:  Hee-Yeon Jung; Jong-Hoon Kim; Yong-Min Ahn; Seong-Chan Kim; Samuel S Hwang; Yong-Sik Kim
Journal:  Hum Psychopharmacol       Date:  2005-01       Impact factor: 1.672

5.  Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease.

Authors:  Kevin Duff; Leigh J Beglinger; Margaret E O'Rourke; Peg Nopoulos; Henry L Paulson; Jane S Paulsen
Journal:  Ann Clin Psychiatry       Date:  2008 Jan-Mar       Impact factor: 1.567

6.  An International Survey-based Algorithm for the Pharmacologic Treatment of Chorea in Huntington's Disease.

Authors:  Jean-Marc Burgunder; Mark Guttman; Susan Perlman; Nathan Goodman; Daniel P van Kammen; Lavonne Goodman
Journal:  PLoS Curr       Date:  2011-08-30

Review 7.  Comparative Pharmacology of Risperidone and Paliperidone.

Authors:  Maria Corena-McLeod
Journal:  Drugs R D       Date:  2015-06

8.  Dopamine imbalance in Huntington's disease: a mechanism for the lack of behavioral flexibility.

Authors:  Jane Y Chen; Elizabeth A Wang; Carlos Cepeda; Michael S Levine
Journal:  Front Neurosci       Date:  2013-07-04       Impact factor: 4.677

  8 in total
  1 in total

Review 1.  Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics.

Authors:  Samantha Alvarez-Herrera; Raúl Escamilla; Oscar Medina-Contreras; Ricardo Saracco; Yvonne Flores; Gabriela Hurtado-Alvarado; José Luis Maldonado-García; Enrique Becerril-Villanueva; Gilberto Pérez-Sánchez; Lenin Pavón
Journal:  Front Endocrinol (Lausanne)       Date:  2020-04-21       Impact factor: 5.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.